COVID - 19 Vaccination Update - Day 417 - Prevention is better than cure

Spread the Message

Read Time:1 Minute, 39 Second

Posted On: 08 MAR 2022 8:44 PM by PIB Delhi

India’s COVID-19 vaccination coverage has crossed 179.31 Crore (1,79,31,52,374) today. More than 16 lakh (16,59,691) Vaccine Doses have been administered till 7 pm today. More than 2.08 Crore (2,08,51,175) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs	1^st Dose	10402281
	2^nd Dose	9978837
	Precaution Dose	4268101
FLWs	1^st Dose	18410813
	2^nd Dose	17466214
	Precaution Dose	6440198
Age Group 15-18 years	1^st Dose	55572285
	2^nd Dose	31983217
Age Group 18-44 years	1^st Dose	552844690
Age Group 18-44 years	2^nd Dose	451567945
Age Group 45-59 years	1^st Dose	202447548
Age Group 45-59 years	2^nd Dose	181842344
Over 60 years	1^st Dose	126539141
	2^nd Dose	113245884
	Precaution Dose	10142876
Cumulative 1^st dose administered		966216758
Cumulative 2^nd dose administered		806084441
Precaution Dose		20851175
Total		1793152374

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 8^th March, 2022 (417^th Day)
HCWs	1^st Dose	45
	2^nd Dose	1176
	Precaution Dose	9451
FLWs	1^st Dose	73
	2^nd Dose	2296
	Precaution Dose	13397
Age Group 15-18 years	1^st Dose	70279
	2^nd Dose	429612
Age Group 18-44 years	1^st Dose	92274
Age Group 18-44 years	2^nd Dose	699367
Age Group 45-59 years	1^st Dose	13805
Age Group 45-59 years	2^nd Dose	160632
Over 60 years	1^st Dose	9264
	2^nd Dose	101060
	Precaution Dose	56960
Cumulative 1^st dose administered		185740
Cumulative 2^nd dose administered		1394143
Precaution Dose		79808
Total		1659691

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.